Table 2.
Absolute effects of rt-PA per 1000 patients treated and between trial heterogeneity, all outcomes
| Effect per 1000 patients treated (95% CI) |
Heterogeneity |
||||
|---|---|---|---|---|---|
| χ2 | Df | p value | |||
| Events within 7 days, treatment up to 6 h after stroke | |||||
| Death (total) | 25 (11 to 39) | 7·34 | 7 | 0·39 | |
| Fatal intracranial haemorrhage | 29 (23 to 36) | 6·29 | 7 | 0·51 | |
| Death (not due to intracranial haemorrhage) | −4 (−16 to 8)* | 5·73 | 4 | 0·22 | |
| Symptomatic intracranial haemorrhage | 58 (49 to 68) | 15·24 | 11 | 0·17 | |
| Symptomatic oedema | −2 (−18 to 13)* | 17·47 | 5 | 0·004 | |
| Events by end of follow-up, treatment up to 6 h after stroke | |||||
| Deaths between 7 days and end of follow–up | −22 (−39 to −4) | 4·88 | 5 | 0·43 | |
| Deaths by end of follow–up | 7 (−11 to 25)* | 17·70 | 11 | 0·09 | |
| Alive and independent (mRS 0–2) | 42 (19 to 66) | 17·06 | 9 | 0·05 | |
| Alive and favourable outcome (mRS 0–1) | 55 (33 to 77) | 21·12 | 9 | 0·01 | |
| Dependent (mRS 3–5) | −50 (−73 to −27)* | 19·08 | 9 | 0·02 | |
| Outcome by time to treatment | |||||
| Alive, favourable outcome (mRS 0–1), <3 h | 87 (46 to 128) | 7·90 | 5 | 0·16 | |
| Alive and independent (mRS 0–2), <3 h | 90 (46 to 135) | 1·87 | 5 | 0·87 | |
| Alive and independent (mRS 0–2), 3–6 h | 18 (−10 to 45)* | 9·86 | 6 | 0·13 | |
| Dead by end of follow-up, <3 h | −15 (−55 to 25)* | 8·26 | 6 | 0·22 | |
| Dead by end of follow-up, 3–6 h | 18 (−3 to 39)* | 10·68 | 6 | 0·10 | |
| Symptomatic intracranial haemorrhage, <3 h | 68 (49 to 87) | 3·12 | 5 | 0·68 | |
| Symptomatic intracranial haemorrhage, 3–6 h | 58 (46 to 70) | 3·55 | 6 | 0·74 | |
| Outcome by age and time to treatment | |||||
| Treatment up to 6 h after stroke | |||||
| Alive and independent (mRS 0–2), ≤80 years | 43 (16 to 70) | 19·22 | 9 | 0·02 | |
| Alive and independent (mRS 0–2), >80 years | 38 (−3 to 79) | 2·14 | 2 | 0·34 | |
| Treatment up to 3 h | |||||
| Alive and independent (mRS 0–2), ≤80 years | 95 (35 to 155) | 3·64 | 5 | 0·60 | |
| Alive and independent (mRS 0–2), >80 years | 96 (35 to 157) | 0·67 | 1 | 0·41 | |
| Treatment between 3–6 h | |||||
| Alive and independent (mRS 0–2), ≤80 years | 23 (−8 to 54) | 8·91 | 6 | 0·18 | |
| Alive and independent (mRS 0–2), >80 years | −5 (−61 to 50) | 0 | 1 | 0·95 | |
rt-PA=recombinant tissue plasminogen activator. Df=degrees of freedom. mRS=modified Rankin Scale.
*
A minus indicates fewer events per 1000 patients treated with rt-PA.